Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

Next Previous
Trial Profile

Phase I Study of Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Feb 2019

At a glance

  • Drugs Ceritinib (Primary) ; Docetaxel (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 31 Oct 2018 Planned End Date changed from 1 Aug 2024 to 1 Oct 2024.
    • 31 Oct 2018 Planned primary completion date changed from 1 Aug 2023 to 1 Oct 2023.
    • 31 Oct 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top